These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 26922989)

  • 21. The Neutralizing Antibody Response to the HIV-1 Env Protein.
    Moore PL
    Curr HIV Res; 2018; 16(1):21-28. PubMed ID: 29173180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.
    deCamp A; Hraber P; Bailer RT; Seaman MS; Ochsenbauer C; Kappes J; Gottardo R; Edlefsen P; Self S; Tang H; Greene K; Gao H; Daniell X; Sarzotti-Kelsoe M; Gorny MK; Zolla-Pazner S; LaBranche CC; Mascola JR; Korber BT; Montefiori DC
    J Virol; 2014 Mar; 88(5):2489-507. PubMed ID: 24352443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
    Verkoczy L; Kelsoe G; Haynes BF
    PLoS Pathog; 2014 May; 10(5):e1004073. PubMed ID: 24853821
    [No Abstract]   [Full Text] [Related]  

  • 26. HIV/AIDS Vaccines: 2018.
    Robinson HL
    Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of humoral immunity in host defense against HIV.
    Baum LL
    Curr HIV/AIDS Rep; 2010 Feb; 7(1):11-8. PubMed ID: 20425053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of prophylactic vaccines against HIV-1.
    Schiffner T; Sattentau QJ; Dorrell L
    Retrovirology; 2013 Jul; 10():72. PubMed ID: 23866844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV vaccine development.
    Watkins DI
    Top Antivir Med; 2011; 19(2):36-7. PubMed ID: 21868820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.
    Pauthner M; Havenar-Daughton C; Sok D; Nkolola JP; Bastidas R; Boopathy AV; Carnathan DG; Chandrashekar A; Cirelli KM; Cottrell CA; Eroshkin AM; Guenaga J; Kaushik K; Kulp DW; Liu J; McCoy LE; Oom AL; Ozorowski G; Post KW; Sharma SK; Steichen JM; de Taeye SW; Tokatlian T; Torrents de la Peña A; Butera ST; LaBranche CC; Montefiori DC; Silvestri G; Wilson IA; Irvine DJ; Sanders RW; Schief WR; Ward AB; Wyatt RT; Barouch DH; Crotty S; Burton DR
    Immunity; 2017 Jun; 46(6):1073-1088.e6. PubMed ID: 28636956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical issues in mucosal immunity for HIV-1 vaccine development.
    Haynes BF; Shattock RJ
    J Allergy Clin Immunol; 2008 Jul; 122(1):3-9; quiz 10-1. PubMed ID: 18468671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
    Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
    Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
    Kwong PD; Mascola JR
    Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in HIV-1 vaccine development.
    Haynes BF; Moody MA; Alam M; Bonsignori M; Verkoczy L; Ferrari G; Gao F; Tomaras GD; Liao HX; Kelsoe G
    J Allergy Clin Immunol; 2014 Jul; 134(1):3-10; quiz 11. PubMed ID: 25117798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development.
    Niessl J; Kaufmann DE
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29921828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody responses to envelope glycoproteins in HIV-1 infection.
    Burton DR; Mascola JR
    Nat Immunol; 2015 Jun; 16(6):571-6. PubMed ID: 25988889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.